UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/643,319	08/19/2003 Michael D. Ruff		M233 1030.1	3826	
	7590 09/10/200 RLYLE SANDRIDGE	EXAMINER			
ATTN: PATENT DOCKETING 32ND FLOOR			SILVERMAN, ERIC E		
P.O. BOX 7037 ATLANTA, GA			ART UNIT	PAPER NUMBER	
,			1618		
			MAIL DATE	DELIVERY MODE	
			09/10/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary		Appl	ication No.	Applicant(s)	Applicant(s)			
		10/6	43,319	RUFF ET AL.				
		Exar	niner	Art Unit				
		ERIC	E. SILVERMAN	1618				
Period fo	The MAILING DATE of this communi r Reply	cation appears o	n the cover sheet with	h the correspondence a	ddress			
WHIC - Exter after - If NO - Failu Any r	CORTENED STATUTORY PERIOD FOR HEVER IS LONGER, FROM THE MASSING (6) MONTHS from the mailing date of this communication for reply is specified above, the maximum state to reply within the set or extended period for reply eply received by the Office later than three months after patent term adjustment. See 37 CFR 1.704(b).	AILING DATE Of 37 CFR 1.136(a). In unication. tutory period will apply will, by statute, cause the	F THIS COMMUNIC no event, however, may a rep and will expire SIX (6) MONT ne application to become ABA	ATION. Oly be timely filed HS from the mailing date of this of NDONED (35 U.S.C. § 133).				
Status								
1)[\]	Responsive to communication(s) filed	d on						
'=	•	b)⊠ This action	is non-final					
′=		<i>-</i>		rs prosecution as to the	e merits is			
<u>ا ا</u> ر	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
	·	o andor Expart	o quayro, 1000 0.2.	11, 100 0.0. 210.				
Dispositi	on of Claims							
•	Claim(s) <u>43-46,49-53 and 55-57</u> is/are pending in the application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.							
5)	S) Claim(s) is/are allowed.							
6)⊠	6) Claim(s) 43-46,49-53 and 55-57 is/are rejected.							
7)	Claim(s) is/are objected to.							
8)□	Claim(s) are subject to restrict	tion and/or elect	ion requirement.					
Applicati	on Papers							
9) <u></u>	The specification is objected to by the	Examiner.						
10)	The drawing(s) filed on is/are:	a) accepted	or b)⊡ objected to b	y the Examiner.				
•	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
	Replacement drawing sheet(s) including	the correction is r	equired if the drawing(s) is objected to. See 37 C	FR 1.121(d).			
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority u	ınder 35 U.S.C. § 119							
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
2) Notic 3) Inforr	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (P [*] nation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date <u>8-13-08,7-15-08</u> .	ГО-948)	Paper No(s)	Immary (PTO-413) /Mail Date ormal Patent Application -				

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 7/15/2008 has been entered.

Claims 43-46, 49-53 and 55-57 are pending in this action.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 43-46, 49-53, and 55-57 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 43 recites "dibasic calcium phosphate dehydrate". This is believed to be a typographical error; it is believed that Applicants' intended "dibasic calcium phosphate dihydrate." Appropriate correction is required.

Claim Rejections - 35 USC § 103

Claims 43-46, 49-53, and 55 remain rejected under 35 U.S.C. 103(a) as being unpatentable over US 5,958,458 to Norling in view of US 5,788,987 to Busetti for reasons of record and those discussed below.

Application/Control Number: 10/643,319 Page 3

Art Unit: 1618

Claims 56 and 57 remain rejected under 35 U.S.C. 103(a) as being unpatentable over Norling in view of Busetti as applied to claims 43-46, 49-53 and 55, and in further view of US 2003/0050228 to Ekwuribe.

Response to Arguments

Applicants' arguments have been fully considered, but are not persuasive.

Applicants' argue that the art does not teach or suggest the use of a core that is exclusively dibasic calcium phosphate dihydrate. Specifically, Applicants' allege that both Norling and Busetti teach the use of active ingredients in the core, or the use of more than one core ingredient. In response, Norling at claim 1 teaches a core comprising a pharmaceutically acceptable inert carrier which may be calcium phosphate. In this claim, the active drug is "present in a layer in the outer surface of the cores." This clearly suggests that there is no active agent in the core, and that the core may be made out of inert carrier alone (calcium phosphate being one such carrier). Busetti shows the utility of one species of calcium phosphate, dibasic calcium phosphate dihydrate, as a core in an insulin delivery system. It is noted that, while Norling may also teach the combination of actives with the inert core, such additional teachings do not detract from the suggestion at claim 1 to use a core having only an inert material. From Busetti, the artisan would expect the species of dibasic calcium phosphate dehydrate to be especially effective. Thus, when all of the teachings of the prior art references are taken together, the idea of using a single-component inert bead "core" coated by an active is known, as is the idea of using a dibasic calcium phosphate dehydrate as the inert component of a core bead for insulin delivery. It therefore follows Application/Control Number: 10/643,319 Page 4

Art Unit: 1618

that the claims represent prima facie obvious subject matter. Applicants' have not separately argued the rejection of claim 56 and 57, and as such, it is understood that Applicants' believe these claims to be patentable only insofar as their parent claims are also patentable; no parent claims are patentable at this time.

Conclusion

No claims are allowed

Any inquiry concerning this communication or earlier communications from the examiner should be directed to ERIC E. SILVERMAN whose telephone number is (571)272-5549. The examiner can normally be reached on Monday to Thursday 7:00 am to 5:00 pm and Friday 7:00 am to noon.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Hartley can be reached on 571 272 0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Eric E Silverman/ Examiner, Art Unit 1618